BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asevedo E, Rizzo LB, Gadelha A, Mansur RB, Ota VK, Berberian AA, Scarpato BS, Teixeira AL, Bressan RA, Brietzke E. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol Behav. 2014;129:194-198. [PMID: 24576679 DOI: 10.1016/j.physbeh.2014.02.032] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Lozupone M, La Montagna M, D'Urso F, Daniele A, Greco A, Seripa D, Logroscino G, Bellomo A, Panza F. The Role of Biomarkers in Psychiatry. Adv Exp Med Biol 2019;1118:135-62. [PMID: 30747421 DOI: 10.1007/978-3-030-05542-4_7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
2 Fahey L, Donohoe G, Broin PÓ, Morris DW. Genes regulated by BCL11B during T-cell development are enriched for de novo mutations found in schizophrenia patients. Am J Med Genet B Neuropsychiatr Genet 2020;183:370-9. [PMID: 32729240 DOI: 10.1002/ajmg.b.32811] [Reference Citation Analysis]
3 Xiu MH, Yang GG, Tan YL, Chen DC, Tan SP, Wang ZR, Yang FD, Okusaga O, Soares JC, Zhang XY. Decreased interleukin-10 serum levels in first-episode drug-naïve schizophrenia: relationship to psychopathology. Schizophr Res 2014;156:9-14. [PMID: 24766914 DOI: 10.1016/j.schres.2014.03.024] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
4 Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res 2018;199:281-4. [PMID: 29499967 DOI: 10.1016/j.schres.2018.02.048] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
5 Wesseling H, Want EJ, Guest PC, Rahmoune H, Holmes E, Bahn S. Hippocampal Proteomic and Metabonomic Abnormalities in Neurotransmission, Oxidative Stress, and Apoptotic Pathways in a Chronic Phencyclidine Rat Model. J Proteome Res 2015;14:3174-87. [PMID: 26043028 DOI: 10.1021/acs.jproteome.5b00105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
6 Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, Gadelha A, Brietzke E. High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry 2015;16:422-9. [PMID: 26212792 DOI: 10.3109/15622975.2015.1062552] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
7 Mohammadi A, Rashidi E, Amooeian VG. Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. Psychiatry Res 2018;265:25-38. [PMID: 29680514 DOI: 10.1016/j.psychres.2018.04.036] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
8 Roomruangwong C, Noto C, Kanchanatawan B, Anderson G, Kubera M, Carvalho AF, Maes M. The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia. Mol Neurobiol. 2019;. [PMID: 31473906 DOI: 10.1007/s12035-019-01737-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
9 Schmitt A, Martins-de-souza D, Akbarian S, Cassoli JS, Ehrenreich H, Fischer A, Fonteh A, Gattaz WF, Gawlik M, Gerlach M, Grünblatt E, Halene T, Hasan A, Hashimoto K, Kim Y, Kirchner S, Kornhuber J, Kraus TF, Malchow B, Nascimento JM, Rossner M, Schwarz M, Steiner J, Talib L, Thibaut F, Riederer P, Falkai P; The Members of the WFSBP Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. The World Journal of Biological Psychiatry 2017;18:330-56. [DOI: 10.1080/15622975.2016.1224929] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Lai CY, Scarr E, Udawela M, Everall I, Chen WJ, Dean B. Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics. World J Psychiatr 2016; 6(1): 102-117 [PMID: 27014601 DOI: 10.5498/wjp.v6.i1.102] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 60] [Article Influence: 12.7] [Reference Citation Analysis]
11 Matsushima J, Kawashima T, Nabeta H, Imamura Y, Watanabe I, Mizoguchi Y, Kojima N, Yamada S, Monji A. Association of inflammatory biomarkers with depressive symptoms and cognitive decline in a community-dwelling healthy older sample: a 3-year follow-up study. J Affect Disord 2015;173:9-14. [PMID: 25462389 DOI: 10.1016/j.jad.2014.10.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
12 Goldsmith DR, Haroon E, Miller AH, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Seidman L, Tsuang M, Woods SW, Walker EF, Perkins DO. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain Behav Immun 2019;76:268-74. [PMID: 30496778 DOI: 10.1016/j.bbi.2018.11.315] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
13 Orsolini L, Sarchione F, Vellante F, Fornaro M, Matarazzo I, Martinotti G, Valchera A, Di Nicola M, Carano A, Di Giannantonio M, Perna G, Olivieri L, De Berardis D. Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. Curr Neuropharmacol 2018;16:583-606. [PMID: 29357805 DOI: 10.2174/1570159X16666180119144538] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
14 [DOI: 10.1101/393173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry 2019;10:892. [PMID: 31908647 DOI: 10.3389/fpsyt.2019.00892] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
16 Darweesh A, Agban M, Mohammed MH, Gabra RH. Association between opioid use disorder (tramadol) and serum level of interleukin-2. Middle East Curr Psychiatry 2020;27. [DOI: 10.1186/s43045-020-00037-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Kalia M, Costa e Silva J. Biomarkers of psychiatric diseases: Current status and future prospects. Metabolism 2015;64:S11-5. [DOI: 10.1016/j.metabol.2014.10.026] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
18 Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016;21:1696-709. [PMID: 26903267 DOI: 10.1038/mp.2016.3] [Cited by in Crossref: 619] [Cited by in F6Publishing: 569] [Article Influence: 103.2] [Reference Citation Analysis]
19 González-Blanco L, García-Portilla MP, García-Álvarez L, de la Fuente-Tomás L, Iglesias García C, Sáiz PA, Rodríguez-González S, Coto-Montes A, Bobes J. Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia? Rev Psiquiatr Salud Ment (Engl Ed) 2019;12:9-16. [PMID: 29724678 DOI: 10.1016/j.rpsm.2018.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tan Y, Li Y, Tan S, Wang Z, Yang FD, Cao B, Zunta-Soares GB, Soares JC, Zhang XY. Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia. Schizophr Res 2015;169:16-21. [PMID: 26549630 DOI: 10.1016/j.schres.2015.10.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
21 Zhang Q, Hong W, Li H, Peng F, Wang F, Li N, Xiang H, Zhang Z, Su Y, Huang Y, Zhang S, Zhao G, Zhou R, Mao L, Lin Z, Cai W, Fang Y, Xie B, Zhao M. Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression. Int J Psychophysiol 2017;114:9-15. [PMID: 28174109 DOI: 10.1016/j.ijpsycho.2017.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
22 Frydecka D, Misiak B, Pawlak-Adamska E, Karabon L, Tomkiewicz A, Sedlaczek P, Kiejna A, Beszłej JA. Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia. Neuropsychiatr Dis Treat 2015;11:575-84. [PMID: 25784812 DOI: 10.2147/NDT.S74672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
23 Malashenkova IK, Krynskiy SA, Khailov NA, Kazanova GV, Velichkovsky BB, Didkovsky NA. The role of cytokines in memory consolidation. Biol Bull Rev 2016;6:126-40. [DOI: 10.1134/s2079086416020055] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Hope S, Hoseth E, Dieset I, Mørch RH, Aas M, Aukrust P, Djurovic S, Melle I, Ueland T, Agartz I, Ueland T, Westlye LT, Andreassen OA. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res 2015;165:188-94. [PMID: 25956633 DOI: 10.1016/j.schres.2015.04.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 8.9] [Reference Citation Analysis]
25 Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. CNSNDDT 2019;18:124-40. [DOI: 10.2174/1871527317666181119115532] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
26 Sperner-unterweger B, Fuchs D. Schizophrenia and psychoneuroimmunology: an integrative view. Current Opinion in Psychiatry 2015;28:201-6. [DOI: 10.1097/yco.0000000000000153] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
27 Morrens M, Overloop C, Coppens V, Loots E, Van Den Noortgate M, Vandenameele S, Leboyer M, De Picker L. The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis. Mol Psychiatry 2022. [PMID: 35484245 DOI: 10.1038/s41380-022-01582-y] [Reference Citation Analysis]
28 Xiu MH, Wang DM, Du XD, Chen N, Tan SP, Tan YL, Yang FD, Cho RY, Zhang XY. Interaction of BDNF and cytokines in executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology 2019;108:110-7. [DOI: 10.1016/j.psyneuen.2019.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
29 Vakalopoulos C. The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis. Front Pharmacol 2014;5:277. [PMID: 25566074 DOI: 10.3389/fphar.2014.00277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
30 Wang X, Huang J, Zhu F. Human Endogenous Retroviral Envelope Protein Syncytin-1 and Inflammatory Abnormalities in Neuropsychological Diseases. Front Psychiatry 2018;9:422. [PMID: 30245643 DOI: 10.3389/fpsyt.2018.00422] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
31 Maqsood R, Stone TW. The Gut-Brain Axis, BDNF, NMDA and CNS Disorders. Neurochem Res 2016;41:2819-35. [PMID: 27553784 DOI: 10.1007/s11064-016-2039-1] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 14.5] [Reference Citation Analysis]
32 Kogan S, Ospina LH, Mittal VA, Kimhy D. The impact of inflammation on neurocognition and risk for psychosis: a critical review. Eur Arch Psychiatry Clin Neurosci 2020;270:793-802. [PMID: 31620871 DOI: 10.1007/s00406-019-01073-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Cattane N, Richetto J, Cattaneo A. Prenatal exposure to environmental insults and enhanced risk of developing Schizophrenia and Autism Spectrum Disorder: focus on biological pathways and epigenetic mechanisms. Neurosci Biobehav Rev 2020;117:253-78. [PMID: 29981347 DOI: 10.1016/j.neubiorev.2018.07.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
34 Prata J, Santos SG, Almeida MI, Coelho R, Barbosa MA. Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations. J Neuroinflammation 2017;14:179. [PMID: 28870209 DOI: 10.1186/s12974-017-0938-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
35 Xiu M, Wang D, Chen S, Du X, Chen D, Chen N, Wang Y, Yin G, Zhang Y, Tan Y, Cho RY, Soares JC, Zhang X. Interleukin-3, symptoms and cognitive deficits in first-episode drug-naïve and chronic medicated schizophrenia. Psychiatry Research 2018;263:147-53. [DOI: 10.1016/j.psychres.2018.02.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Misiak B, Stańczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res 2018;192:16-29. [PMID: 28416092 DOI: 10.1016/j.schres.2017.04.015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 15.8] [Reference Citation Analysis]
37 Goldsmith DR, Rapaport MH. Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Front Psychiatry 2020;11:46. [PMID: 32153436 DOI: 10.3389/fpsyt.2020.00046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]